Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

Prior treatment

• Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, and unable to be controlled by oral antihypertensive drugs.
• Previous history of diagnosed viral hepatitis and tuberculosis.

Other illness

• Intracranial hemorrhage confirmed by CT or MRI.
• Allergic to contrast agents.
• Allergic to baricitinib or having contraindications for using baricitinib.
• Recent history of using other JAK inhibitors or potent immunosuppressants, including but not limited to the combined use with potent immunosuppressive drugs such as azathioprine, tacrolimus, tofacitinib and fedratinib, etc. Tortuous arteries make the thrombectomy device unable to reach the target blood vessel.

Lab values

• Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR \>1.7.
• Hemoglobin value \<8g/L.

Age

• mRS score\>2 for patients \<80 years, or mRS score\>1 for those ≥80 years before onset.

Other

• Pregnant or lactating women.
• Participating in other clinical studies.

• Age is 18 years old or above.
• Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA.
• Randomized within 24h after the onset.
• The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination;
• The mTICI score after endovascular treatment (EVT) is above 2b.
• informed consent.